A transgenic mouse developed at Cincinnati Children’s to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) may play a key role in saving lives during the COVID-19 virus pandemic. One of the genetically engineered mouse strain’s inventors–Cincinnati Children’s cancer pathologist Gang Huang, PhD– is co-investigator on a small clinical trial that successfully tested a drug used to treat to HLH (ruxolitinib) to dramatically reverse respiratory and multi-system inflammation in severely ill COVID-19 patients.
- Novel hydrogen fuel purification membrane paves the way for greener future
- Invasive weed may help treat some human diseases, researchers find
- More than 2/3 of Indiana nursing home staff would take COVID-19 vaccine
- Post-Fontan liver fibrosis goes under the radar
- Research offers insights on how night shift work increases cancer risk